1419 results about "Epilepsy" patented technology

Methods of stimulating a vagus nerve include providing at least one implantable stimulator with at least two electrodes, configuring the electrodes to apply stimulation that unidirectionally propagates action potentials along a vagus nerve, and applying the stimulation to the vagus nerve to effectively select afferent fibers, thereby treating at least one of epilepsy and depression while limiting side effects of bidirectional stimulation. At least one of the electrodes comprises a leadsless electrode.

Disclosed are devices and methods for detecting, preventing, and / or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns. The disclosed methods may be useful in the detection, prevention, and / or treatment of a variety of indications, such as epilepsy, Parkinson's Disease, Huntington's disease, Alzheimer's disease, depression, bipolar disorder, phobia, schizophrenia, multiple personality disorder, migraine or headache, concussion, attention deficit hyperactivity disorder, eating disorder, substance abuse, and anxiety. The disclosed methods may also be used in combination with other peripheral stimulation techniques.

The present invention provides methods and systems for patient-specific seizure onset detection. In one embodiment, at least one EEG waveform of the patient is recorded, and at least one epoch (sample) of the waveform is extracted. The waveform sample is decomposed into one or more subband signals via a wavelet decomposition of the waveform sample, and one or more feature vectors are computed based on the subband signals. A seizure onset can then be identified based on classification of the feature vectors to a seizure or a non-seizure class by comparing the feature vectors with a decision measure previously computed for that patient. The decision measure can be derived based on reference seizure and non-seizure EEG waveforms of the patient. In another aspect, similar methodology is employed for automatic detection of alpha waves. In other aspects, the invention provides diagnostic and imaging systems that incorporate the above seizure-onset and alpha-wave detection methodology.

This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.

Introducing one or more stimulating drugs to the brain and / or applying electrical stimulation to the brain is used to treat epilepsy. At least one implantable system control unit (SCU) produces electrical pulses delivered via electrodes implanted in the brain and / or drug infusion pulses delivered via a catheter implanted in the brain. The stimulation is delivered to targeted brain structures to adjust the activity of those structures. The small size of the SCUs of the invention allow SCU implantation directly and entirely within the skull and / or brain. Simplicity of the preferred systems and methods and compactness of the preferred system are enabled by the modest control parameter set of these SCU, which do not require or include a sensing feature.

A leadless intravascular sensor (100, 200) uses the body tissue as a communication medium. The implantable intravascular device has a tubular stent-like structure (102) for intravascular fixation with embedded microcircuits to allow bipolar and unipolar sensing of cardiac and neurologic electrical activity, sensing of other physiologic signals, local electrical stimulation (cardiac pacing and defibrillation; neurologic stimulation and seizure therapy) as well as the ability to communicate with other implanted and non implanted devices via radio frequency and / or optical communication and / or analog signal communication using the body tissue as the conducting medium. The device can also be used in the extravascular or perivascular space. In this form, it has an open / flexible ring that can be adjusted, or self-adjusts to provide no pressure or required contact around the vessel or target region.

A method and system for neuromodulating vagus nerve(s) to provide therapy for neurological and neuropsychiatric disorders comprises implantable and external components. The pulsed electrical stimulation to vagus nerve(s) is used for disorders such as epilepsy, depression, anxiety disorders, neurogenic pain, compulsive eating disorders, obesity, dementia including Alzheimer's disease, and migraines. The pulsed electrical stimulation to vagus nerve(s) may be provided using one of the following stimulation systems, such as: a) an implanted stimulus-receiver with an external stimulator; b) an implanted stimulus-receiver comprising a high value capacitor for storing charge, used in conjunction with an external stimulator; c) a programmer-less implantable pulse generator (IPG) which is operable with a magnet; d) a programmable implantable pulse generator; e) a combination implantable device comprising both a stimulus-receiver and a programmable IPG; and f) an IPG comprising a rechargeable battery. In one embodiment, the external components such as the programmer or external stimulator may comprise a telemetry means for networking. The telemetry means therefore allows for interrogation or programming of implanted device, from a remote location over a wide area network.

The invention provides a micro-control neuroprosthetic device and methods for predicting and controlling epileptic neuronal activity. The device includes a detection system that detects and collects electrophysiological information comprising action potentials from single neurons and ensembles of neurons in a neural structure such as an epileptogenic region of the brain in a subject. An analysis system included in the neuroprosthetic device evaluates the electrophysiological information and performs a real-time extraction of neuron firing features from which the system determines when stimulus intervention is required. The neuroprosthetic device further comprises a stimulation intervention system that provides stimulus output signals having a desired stimulation frequency and stimulation intensity directly to the neural structure in which abnormal neuronal activity is detected. The analysis system further analyzes collected electrophysiological information during or following stimulus intervention to assess the effects of the stimulation intervention and to provide outputs to maintain or modify the stimulation intervention.

The present invention relates to novel compounds, in particular novel thieno-pyridine and thieno-pyrimidine derivatives according to Formula (I), wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

A method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.

Methods, systems, and apparatus for assessing a state of an epilepsy disease or a comorbidity thereof are provided. The methods comprise receiving at least one autonomic index, neurologic index, stress marker index, psychiatric index, endocrine index, adverse effect of therapy index, physical fitness index, or quality of life index of a patient; comparing the at least one index to at least one reference value; and assessing a state of an epilepsy disease or a body system of the patient based on the comparison. A computer readable program storage device encoded with instructions that, when executed by a computer, perform the method described above is also provided. A medical device system capable of implementing the method described above is also provided.

The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.

Disclosed are devices and methods for detecting, preventing, and / or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns. The disclosed methods may be useful in the detection, prevention, and / or treatment of a variety of indications, such as epilepsy, Parkinson's Disease, Huntington's disease, Alzheimer's disease, depression, bipolar disorder, phobia, schizophrenia, multiple personality disorder, migraine or headache, concussion, attention deficit hyperactivity disorder, eating disorder, substance abuse, and anxiety. The disclosed methods may also be used in combination with other peripheral stimulation techniques.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

A method and device for treating epilepsy are disclosed which provide for electrical, chemical or magnetic stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of epilepsy. Deep brain stimulation is combined with vagus nerve stimulation to enhance symptomatic relief of the disorder. Some embodiments also employ a sensing capability to optimize the therapeutic treatment regimen.

A leadless intravascular sensor (100, 200) uses the body tissue as a communication medium. The implantable intravascular device has a tubular stent-like structure (102) for intravascular fixation with embedded microcircuits to allow bipolar and unipolar sensing of cardiac and neurologic electrical activity, sensing of other physiologic signals, local electrical stimulation (cardiac pacing and defibrillation; neurologic stimulation and seizure therapy) as well as the ability to communicate with other implanted and non implanted devices via radio frequency and / or optical communication and / or analog signal communication using body tissue as the conducting medium. The device can also be used in the extravascular or perivascular space. In this form, it has an open / flexible ring that can be adjusted, or self-adjusts to provide no pressure or required contact around the vessel or target region.

A system and method for applying electrical stimulation or drug infusion to nervous tissue of a patient to treat epilepsy, movement disorders, and other indications uses at least one implantable system control unit (SCU) (110), including an implantable signal / pulse generator (IPG) and one or more electrodes (152, 152′). The IPG is implanted in the mastoid area (143) of the skull (140) and communicates with at least one external appliance (230), such as a Behind-the-Ear (BTE) unit (100). In a preferred embodiment, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters.

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders. One aspect of the implantable medical device is that it includes an electronics enclosure, a substrate integral to the electronics enclosure, and a monolithic feed-through integral to the electronics enclosure and the substrate. In some embodiments, the implantable medical device can include a fixation apparatus for attaching the device to a patient.

The present invention provides compounds that block calcium channels and have the Formula I:The present invention also provides pharmaceutical compositions containing the compounds of Formula I and methods of using them to treat stroke, cerebral ischemia, head trauma, and epilepsy.

An apparatus, system, and method are disclosed for detecting seizure symptoms in an individual 102. A sensor module 202 receives physiological data for an individual 102 from one or more sensors 110, 112, such as a heart activity sensor. A feature detection module 204 detects a predefined feature 500, 520, 530, 540 in the physiological data. The predefined feature 500, 520, 530, 540 is associated with a seizure or another medical condition. An alert module 206 broadcasts an alert in response to the feature detection module 204 detecting the predefined feature 500, 520, 530, 540.

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders. One aspect of the implantable medical device is that it includes an electronics enclosure, a substrate integral to the electronics enclosure, and a monolithic feed-through integral to the electronics enclosure and the substrate. In some embodiments, the implantable medical device can include a fixation apparatus for attaching the device to a patient.

Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and / or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition.

An implantable neurostimulator for treating disorders such as epilepsy, pain, movement disorders and depression includes a detection subsystem capable of detecting a physiological condition and a therapy subsystem capable of providing a course of therapy in response to the condition. The therapy subsystem includes an auto-adjust module for automatically adjusting one or more parameters of the therapy so that the therapy subsystem can provide an adjusted parameter to the patient and solicit the patient's feedback concerning the adjustment without requiring the presence of, or immediate involvement with, a clinician or physician. The patient feedback can be analyzed by computer, clinician or a combination of both to determine an optimal range of parameters for subsequent courses of therapy. In this manner, information useful in tuning the neurostimulator therapy parameters to optimize them for individual patient can be acquired automatically outside of the traditional clinical setting, saving time and minimizing patient fatigue that otherwise would be experience in marathon, in-clinic tuning sessions. The auto-adjust module also can be configured to prompt the patient to provide feedback even when parameters are not being adjusted, so as to acquire information for a baseline or about any placebo effect when the patient is otherwise expecting changes to the therapy to be made.

The present invention relates to devices and methods of use thereof for detection of biomolecules, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and / or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more biomolecules including, but not limited to, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson's disease, brain injuries, spinal cord injuries, and cancer. The invention also provides methods of differentiating white matter from gray matter. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using sensors. The invention further provides methods of measuring the neurotoxicity of a material by comparing microvoltammograms of a neural tissue in the presence and absence of the material using the inventive sensors.

Described herein are methods, devices and systems for neuromodulation of deep brain targets using a combination of transcranial magnetic stimulation (TMS) and transcranial direct current (DC) stimulation to reduce or eliminate side-effects when modulating one or more deep brain targets. For example, transcranial magnetic stimulation of a deep brain target may be synchronized with modulation of more superficially located cortical brain regions using transcranial direct current stimulation to prevent seizures and other side effects. Systems configured to regulate (or synchronize) the application of transcranial magnetic stimulation of deep brain targets and transcranial direct current stimulation are also described.

Methods and apparatus for providing vagus nerve stimulation for the treatment of diseases such as depression and epilepsy that do not require an onboard, implanted power supply. Power may be supplied from outside of the body by near-field inductive coupling with an external power supply provided in a support article (e.g., garment) worn by the patient. Power may also be supplied by providing an antenna for harvesting ambient RF energy and converting it into DC power. In addition, the methods and apparatus provide for remote, wireless programming of the parameters that specify the nature of current pulses provided to the vagus nerve by probes implanted in the body of the patient. The preferred stimulation profile is 1-2 milliamp pulses of 250 microseconds in duration at a frequency of 20 to 30 Hz, wherein the profile is repeatedly on for 30 seconds and off for 5 minutes.

Devices, systems and methods are disclosed for treating a variety of diseases and disorders that are primarily or at least partially driven by an imbalance in neurotransmitters in the brain, such as asthma, COPD, depression, anxiety, epilepsy, fibromyalgia, and the like. The invention involves the use of an energy source comprising magnetic and / or electrical energy that is transmitted non-invasively to, or in close proximity to, a selected nerve to temporarily stimulate, block and / or modulate the signals in the selected nerve such that neural pathways are activated to release inhibitory neurotransmitters in the patient's brain.

The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.

The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.